The BGOG is a member of the European Network of Gynaecological Oncological Trial Groups (ENGOT).


 

BGOG-EN2

A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

Learn More ->

BGOG-v-1

Groningen International Study on Sentinel Lymph Nodes in Vulvar Cancer II – An observational study

Learn More ->

BGOG-ov-9

A Randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.

Learn More ->

BGOG-ov-7

Randomized Phase III trial of Paclitaxel-Carboplatin with or without concomittant and maintenance AMG386 as First-line therapy of Stage III-IV ovarian, fallopian tube and peritoneal carcinoma.

Learn More ->


BGOG-ov-6

A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Learn More ->

BGOG-ov-5

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.

Learn More ->

BGOG-ov-4

Phase III Randomised Study of Bevacizumab plus Chemotherapy versus Chemotherapy alone in Patients with Platinum Resistant Ovariumcancer.

Learn More ->

BGOG-ov-3

A Multicentre, Randomized, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination with Standard Treatment of Carboplatin and Paclitaxel Compared to Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer.

Learn More ->


BGOG-ov-2

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Learn More ->

BGOG-ov-1

Stealth Liposomal Doxorubicin vs Carboplatin/Paclitaxel in patients with ovarian cancer recurrence between six and twelve months after previous platinum based chemotherapy: phase III multicenter randomized study.

Learn More ->